Exact Sciences (FRA:EXK) Common Stock : €2 Mil (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Exact Sciences Common Stock?

Exact Sciences's quarterly common stock declined from Jun. 2024 (€2 Mil) to Sep. 2024 (€2 Mil) but then increased from Sep. 2024 (€2 Mil) to Dec. 2024 (€2 Mil).

Exact Sciences's annual common stock declined from Dec. 2022 (€2 Mil) to Dec. 2023 (€2 Mil) but then increased from Dec. 2023 (€2 Mil) to Dec. 2024 (€2 Mil).

Exact Sciences Common Stock Historical Data

The historical data trend for Exact Sciences's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Common Stock Chart

Exact Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

1.31

1.54

1.68

1.66

1.77

Exact Sciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															1.66	1.69	1.72	1.67	1.77

Exact Sciences Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Exact Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (FRA:EXK) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

EXAS:USA EXAS:Mexico EXK:Germany

Address

5505 Endeavor Lane, Madison, WI, USA, 53719

Website

https://www.exactsciences.com

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.